These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

244 related articles for article (PubMed ID: 26648061)

  • 1. Nucleoside Inhibitors of Hepatitis C Virus NS5B Polymerase: A Systematic Review.
    Xie Y; Ogah CA; Jiang X; Li J; Shen J
    Curr Drug Targets; 2016; 17(13):1560-76. PubMed ID: 26648061
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Design, synthesis, and structure-activity relationships of novel imidazo[4,5-c]pyridine derivatives as potent non-nucleoside inhibitors of hepatitis C virus NS5B.
    Liu M; Xu Q; Guo S; Zuo R; Hong Y; Luo Y; Li Y; Gong P; Liu Y
    Bioorg Med Chem; 2018 May; 26(9):2621-2631. PubMed ID: 29681484
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Resistance analysis and characterization of NITD008 as an adenosine analog inhibitor against hepatitis C virus.
    Qing J; Luo R; Wang Y; Nong J; Wu M; Shao Y; Tang R; Yu X; Yin Z; Sun Y
    Antiviral Res; 2016 Feb; 126():43-54. PubMed ID: 26724382
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hepatitis C therapy with HCV NS5B polymerase inhibitors.
    Soriano V; Vispo E; de Mendoza C; Labarga P; Fernandez-Montero JV; Poveda E; Treviño A; Barreiro P
    Expert Opin Pharmacother; 2013 Jun; 14(9):1161-70. PubMed ID: 23621117
    [TBL] [Abstract][Full Text] [Related]  

  • 5. HCV Genotype 6a Escape From and Resistance to Velpatasvir, Pibrentasvir, and Sofosbuvir in Robust Infectious Cell Culture Models.
    Pham LV; Ramirez S; Gottwein JM; Fahnøe U; Li YP; Pedersen J; Bukh J
    Gastroenterology; 2018 Jun; 154(8):2194-2208.e12. PubMed ID: 29454794
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 2-Heteroarylimino-5-arylidene-4-thiazolidinones as a new class of non-nucleoside inhibitors of HCV NS5B polymerase.
    Küçükgüzel I; Satılmış G; Gurukumar KR; Basu A; Tatar E; Nichols DB; Talele TT; Kaushik-Basu N
    Eur J Med Chem; 2013 Nov; 69():931-41. PubMed ID: 24161679
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synthesis of potent and broad genotypically active NS5B HCV non-nucleoside inhibitors binding to the thumb domain allosteric site 2 of the viral polymerase.
    Pierra Rouvière C; Amador A; Badaroux E; Convard T; Da Costa D; Dukhan D; Griffe L; Griffon JF; LaColla M; Leroy F; Liuzzi M; Loi AG; McCarville J; Mascia V; Milhau J; Onidi L; Paparin JL; Rahali R; Sais E; Seifer M; Surleraux D; Standring D; Dousson C
    Bioorg Med Chem Lett; 2016 Sep; 26(18):4536-4541. PubMed ID: 27520942
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combination therapies with NS5A, NS3 and NS5B inhibitors on different genotypes of hepatitis C virus in human hepatocyte chimeric mice.
    Shi N; Hiraga N; Imamura M; Hayes CN; Zhang Y; Kosaka K; Okazaki A; Murakami E; Tsuge M; Abe H; Aikata H; Takahashi S; Ochi H; Tateno-Mukaidani C; Yoshizato K; Matsui H; Kanai A; Inaba T; McPhee F; Gao M; Chayama K
    Gut; 2013 Jul; 62(7):1055-61. PubMed ID: 23322441
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Non-nucleoside inhibitors of the hepatitis C virus NS5B RNA-dependant RNA polymerase: 2-aryl-3-heteroaryl-1,3-thiazolidin-4-one derivatives.
    Rawal RK; Katti SB; Kaushik-Basu N; Arora P; Pan Z
    Bioorg Med Chem Lett; 2008 Dec; 18(23):6110-4. PubMed ID: 18947995
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sofosbuvir (Sovaldi°). Active against hepatitis C virus, but evaluation is incomplete .
    Prescrire Int; 2015 Jan; 24(156):5-10. PubMed ID: 25734194
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Discovery of Novel Hepatitis C Virus NS5B Polymerase Inhibitors by Combining Random Forest, Multiple e-Pharmacophore Modeling and Docking.
    Wei Y; Li J; Qing J; Huang M; Wu M; Gao F; Li D; Hong Z; Kong L; Huang W; Lin J
    PLoS One; 2016; 11(2):e0148181. PubMed ID: 26845440
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In Vitro Antiviral Activity and Resistance Profile Characterization of the Hepatitis C Virus NS5A Inhibitor Ledipasvir.
    Cheng G; Tian Y; Doehle B; Peng B; Corsa A; Lee YJ; Gong R; Yu M; Han B; Xu S; Dvory-Sobol H; Perron M; Xu Y; Mo H; Pagratis N; Link JO; Delaney W
    Antimicrob Agents Chemother; 2016 Jan; 60(3):1847-1853. PubMed ID: 26824950
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A review on an update of NS5B polymerase hepatitis C virus inhibitors.
    Varshney J; Sharma PK; Sharma A
    Eur Rev Med Pharmacol Sci; 2012 May; 16(5):667-71. PubMed ID: 22774409
    [TBL] [Abstract][Full Text] [Related]  

  • 14. New NS5B polymerase inhibitors for hepatitis C.
    Legrand-Abravanel F; Nicot F; Izopet J
    Expert Opin Investig Drugs; 2010 Aug; 19(8):963-75. PubMed ID: 20629614
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recent advances on the synthesis of hepatitis C virus NS5B RNA-dependent RNA-polymerase inhibitors.
    Zhao C; Wang Y; Ma S
    Eur J Med Chem; 2015 Sep; 102():188-214. PubMed ID: 26276434
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chemical genetics-based discovery of indole derivatives as HCV NS5B polymerase inhibitors.
    Jin G; Lee S; Choi M; Son S; Kim GW; Oh JW; Lee C; Lee K
    Eur J Med Chem; 2014 Mar; 75():413-25. PubMed ID: 24561671
    [TBL] [Abstract][Full Text] [Related]  

  • 17. HCV NS5B polymerase inhibitors.
    Watkins WJ; Ray AS; Chong LS
    Curr Opin Drug Discov Devel; 2010 Jul; 13(4):441-65. PubMed ID: 20597029
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hepatitis C virus genetic variability and the presence of NS5B resistance-associated mutations as natural polymorphisms in selected genotypes could affect the response to NS5B inhibitors.
    Di Maio VC; Cento V; Mirabelli C; Artese A; Costa G; Alcaro S; Perno CF; Ceccherini-Silberstein F
    Antimicrob Agents Chemother; 2014 May; 58(5):2781-97. PubMed ID: 24590484
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sofosbuvir susceptibility of genotype 1 to 6 HCV from DAA-naïve subjects.
    Han B; Martin R; Xu S; Parvangada A; Svarovskaia ES; Mo H; Dvory-Sobol H
    Antiviral Res; 2019 Oct; 170():104574. PubMed ID: 31394118
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vitro selection of resistance to sofosbuvir in HCV replicons of genotype-1 to -6.
    Xu S; Doehle B; Rajyaguru S; Han B; Barauskas O; Feng J; Perry J; Dvory-Sobol H; Svarovskaia ES; Miller MD; Mo H
    Antivir Ther; 2017; 22(7):587-597. PubMed ID: 28248189
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.